Table 3.
Comparison of the composition of FA in adipose tissue between patients with nephrolithiasis and the control group.
| FA (provided by percentage of total amount) | Uric acid* (n=15) | Calcium oxalate/phosphate# (n=56) | Control## (n=100) | P value |
|---|---|---|---|---|
| Mean ± Standard deviation | ||||
| C 18: 1×ω**9 | 44.37±3.35 | 42.40±4.38 | 22.71±3.69 | *,#,##p<0.0001 |
| C 20: 1ω9 | 1.09±0.21 | 1.03±0.56 | 0.56±0.48 | *,#,##p<0.0001 |
| C 18: 3ω3 | 0.15±0.03 | 0.20±0.11 | 1.12±0.54 | *,#,##p<0.0001 |
| C 22: 5ω3 | 0.19±0.09 | 0.20±0.15 | 0.39±0.27 | *,#,##p=0.002 |
| Ratio of ω3/ω6 | 0.05±0.02 | 0.04±0.02 | 1.13±0.28 | *,#,##p<0.0001 |
| Total SFA (C 14: 0 + C 16: 0 + C 18: 0) | 34.67±3.03 | 33.55±2.81 | 32.14±5.29 |
*,##p=1.0 #,##p=0.608 |
| Total MUFA | 53.07±3.54 | 51.78±3.84 | 26.2±4.27 | *,#,##p<0.0001 |
| Total PUFA | 12.66±2.47 | 14.67±3.47 | 35.13±4.84 | *,#,##p<0.0001 |
| PUFA/SFA | 0.37±0.085 | 0.44±0.12 | 1.13±0.29 | *,#,##p<0.0001 |
| ∑*** ω3 | 0.63±0.26 | 0.7±0.44 | 4.5±1.46 | *,#,##p<0.0001 |
| ∑ ω6 | 12.03±2.33 | 13.97±3.13 | 27.92±4.56 | *,#,##p<0.0001 |
| C 14: 0 | 3.33±0.74 | 3.56±3.5 | 4.5±2.34 | p>0.05 |
| C 16: 0 | 24.88±1.74 | 24.8±2.04 | 21.91±2.4 |
*,##p=0.001 #,##p<0.0001 |
| C 18: 0 | 6.06±1.34 | 5.19±1.09 | 6.49±1.05 |
*,#,##p>0.05 #,##p<0.0001 |
| C 16: 1ω7 | 5.08±1.68 | 5.7±1.68 | 3.48±0.99 |
*,##p=0.003 #,##p<0.0001 |
| C 18: 2ω6 | 11.75±2.3 | 13.58±2.99 | 22.59±3.98 | *,#,##p<0.0001 |
| C 20: 4ω6 | 0.28±0.1 | 0.39±0.24 | 5.33±1.11 | *,#,##p<0.0001 |
| C 20: 5ω3 | 0.09±0.05 | 0.11±0.07 | 1.06±0.68 | *,#,##p<0.0001 |
| C 22: 6ω3 | 0.19±0.12 | 0.19±0.15 | 1.93±0.73 | *,#,##p<0.0001 |
SFA – saturated fatty acids; MUFA – monounsaturated fatty acids; PUFA – polyunsaturated fatty acids; * – patients with uric acid kidney stones; # – patients with calcium oxalate/phosphate kidney stones; ## – control group; C 18: 1× – number of carbon atoms and double bonds; ω** – position of double bond between carbon atoms in the molecule; ∑*** – total sum.